Global Bronchodilators Market 2017-2021


◆タイトル:Global Bronchodilators Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥371,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥530,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。





About BronchodilatorsBronchodilators are a type of medication, which make breathing easy by relaxing the muscles in the lungs and widening the airways (bronchi). They are used to treat the breathing problems, majorly asthma and COPD.
Short-acting bronchodilators are the first-line therapy, which is widely used in bronchodilators. These agents have a short-term (2-4 hours) duration of action and therefore require multiple dosages.
Whereas, long-acting bronchodilators, which are introduced recently, have an extended period of action. They reduce the process of multiple dosages. Therefore, they are more effective than the short-term bronchodilators.

Technavio’s analysts forecast the global bronchodilators market to grow at a CAGR of 4.78% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global bronchodilators market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Bronchodilators Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• GlaxoSmithKline

[Other prominent vendors]
• ALK-Abello
• Amgen
• Array BioPharma
• Astellas Pharma
• Atopix Therapeutics
• CHIESI Farmaceutici
• Dynavax Technologies
• Kissei Pharmaceutical
• Kyowa Hakko Kirin
• MediciNova
• Mitsubishi Tanabe Pharma
• Mundipharma International
• Nycomed Pharma
• Oxagen
• Pearl Therapeutics
• Pharmaxis
• Pulmagen Therapeutics
• Regeneron Pharmaceuticals
• Revalesio
• Sanofi
• SolAeroMed
• Stallergenes Greer
• sterna biologicals
• Synairgen
• Theron Pharmaceuticals
• UCB Pharma
• Verona Pharma

[Market driver]
• Market potential toward mAb
• For a full, detailed list, view our report

[Market challenge]
• Increased preference for CAM
• For a full, detailed list, view our report

[Market trend]
• Innovative technologies for drug delivery
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Pipeline analysis

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Market segmentation by drug class
• Anticholinergic bronchodilators
• Adrenergic bronchodilators
• Bronchodilator combinations
• Methylxanthines

PART 08: Geographical segmentation
• Bronchodilators market in Americas
• Bronchodilators market in EMEA
• Bronchodilators market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
Innovative technologies for drug delivery
Growing usage of home healthcare devices
Strong product pipeline

PART 12: Vendor landscape
• Competitive scenario

PART 13: Key vendor analysis
• AstraZeneca
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Types of bronchodilators
Exhibit 02: Pipeline landscape
Exhibit 03: Pipeline analysis
Exhibit 04: Usage of bronchodilators
Exhibit 05: Global bronchodilators market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global bronchodilators market
Exhibit 07: Five forces analysis
Exhibit 08: Global anticholinergic bronchodilators market 2016-2021 ($ millions)
Exhibit 09: Global adrenergic bronchodilators market 2016-2021 ($ millions)
Exhibit 10: Global bronchodilator combinations market 2016-2021 ($ millions)
Exhibit 11: Global methylxanthines bronchodilators market 2016-2021 ($ millions)
Exhibit 12: Global bronchodilators market based on geography 2016 and 2021 (%)
Exhibit 13: Bronchodilators market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Bronchodilators market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Bronchodilators market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Bronchodilators market in APAC 2016-2021 ($ millions)
Exhibit 20: Recent approvals in mAb for bronchodilators market
Exhibit 21: Drugs expected to get approval in forecast period
Exhibit 22: Recent approvals in bronchodilators market
Exhibit 23: Drug approvals in COPD drugs market in past three years
Exhibit 24: COPD drug molecules in the stage of registration
Exhibit 25: Competitive structure analysis of global bronchodilators market 2016
Exhibit 26: Strategic success factors of companies in global bronchodilators market
Exhibit 27: AstraZeneca: Strength assessment
Exhibit 28: AstraZeneca: Strategy assessment
Exhibit 29: AstraZeneca: Opportunity assessment
Exhibit 30: Boehringer Ingelheim: Strength assessment
Exhibit 31: Boehringer Ingelheim: Strategy assessment
Exhibit 32: Boehringer Ingelheim: Opportunity assessment
Exhibit 33: F. Hoffmann-La Roche: Strength assessment
Exhibit 34: F. Hoffmann-La Roche: Strategy assessment
Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 36: GlaxoSmithKline: Strength assessment
Exhibit 37: GlaxoSmithKline: Strategy assessment
Exhibit 38: GlaxoSmithKline: Opportunity assessment


AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline, ALK-Abello, Amgen, Array BioPharma, ASMACURE, Astellas Pharma, Atopix Therapeutics, CHIESI Farmaceutici, Dynavax Technologies, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma International, Nycomed Pharma, Oxagen, Pearl Therapeutics, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, Sanofi, SolAeroMed, Stallergenes Greer, sterna biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, and Verona Pharma.